Valuation: GENFIT

Market Cap 720M 841M 672M 617M 1.16B 80.5B 1.18B 7.97B 3.11B 40.34B 3.16B 3.09B 134B P/E 2026 *
37.2x
P/E 2027 * 95.6x
Enterprise Value 669M 782M 624M 573M 1.08B 74.79B 1.1B 7.41B 2.89B 37.48B 2.93B 2.87B 124B EV / Sales 2026 *
6.68x
EV / Sales 2027 * 5.27x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+5.42%
Current month-4.11%
1 month+3.86%
3 months+64.32%
6 months+78.91%
Current year+174.51%
1 week 12.94
Extreme 12.94
14.74
1 month 12.6
Extreme 12.6
15.4
Current year 5.06
Extreme 5.055
15.4
1 year 3.58
Extreme 3.578
15.4
3 years 3.3
Extreme 3.305
15.4
5 years 2.96
Extreme 2.964
15.4
10 years 2.96
Extreme 2.964
21.74
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.10%+5.42% - - 840M
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+4.89%+485.92%+609.31% 46.01B
-2.04%+3.67%+19.32%+88.19% 42.85B
+2.72%+6.31%+33.70%+19.78% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+5.34%+31.63%+149.21% 16.98B
-1.85%+3.54% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.50%+3.90%+83.13%+45.46% 13.84B
Average +0.24%+2.01%+85.44%+127.38% 30.51B
Weighted average by Cap. +0.30%+2.37%+105.48%+151.60%

Financials

2026 *2027 *
Net sales 100M 117M 93.49M 85.78M 161M 11.2B 164M 1.11B 432M 5.61B 439M 430M 18.58B 124M 145M 116M 106M 200M 13.86B 203M 1.37B 535M 6.95B 544M 532M 23B
Net income 22.88M 26.72M 21.35M 19.59M 36.8M 2.56B 37.53M 253M 98.71M 1.28B 100M 98.15M 4.24B 6.8M 7.94M 6.34M 5.82M 10.94M 760M 11.15M 75.27M 29.34M 381M 29.82M 29.17M 1.26B
Net Debt -51.12M -59.7M -47.69M -43.76M -82.23M -5.71B -83.85M -566M -221M -2.86B -224M -219M -9.48B -66.17M -77.29M -61.74M -56.65M -106M -7.4B -109M -732M -286M -3.71B -290M -284M -12.27B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
20/08/26 14.00 -2.10% 7,373
19/08/26 €14.30 +4.69% 10,242
18/08/26 €13.66 -1.44% 2,077
17/08/26 €13.86 +7.11% 11,667
14/08/26 €12.94 -2.56% 7,281
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.40EUR
Average target price
15.90EUR
Spread / Average Target
+10.42%

Quarterly revenue - Rate of surprise